183 results about "Peptichemio" patented technology

The invention relates to an oral medicinal composition formulation for treating peptic ulcer. The composition comprises esomeprazole, antiacid sodium bicarbonate and a medicinally acceptable carrier, wherein the esomeprazole contains an acid-sensitive proton pump inhibitor; and the antiacid sodium bicarbonate can improve the stability of the proton pump inhibitor. The invention also relates to a preparation method of the medicinal composition. Two active ingredients are integrated into one fixed unit formulation, so that response is quick, a medicinal scheme is simplified in the process of treating the peptic ulcer, and the compliance of a patient is improved.

Novel thiadiazole compounds are provided, which are effective as proton pumps inhibitors, useful in treating peptic ulcers by inhibition of the proton pump enzyme H+/K+-ATPase. The compounds are 3-substituted 1,2,4-thiadiazolo [4,5- alpha ]benzimidazole and 3-substituted imidazo[1,2-d]-1,2,4-thiadiazoles corresponding to the general formula: where X and Z either represent an optionally substituted benzene ring fused to the diazole nucleus, or represent a variety of independent chemical groupings (hydrogen, lower alkyl, halo, etc.) and Y is selected from a wide range, e.g. heterocyclics and carbonyl groups.

The invention discloses a compound or its salt shown in the formula (I) and usage of the compound as a potassium competitive acid blocker or a gastric acid secretion inhibitor. The compound has a proton pump (H+/K+)-ATPase inhibitory effect and can be used for preventing, treating and inhibiting diseases related to gastric acid secretion, such as peptic ulcer, zollinger-ellison syndromes, gastritis, erosive esophagitis, reflux esophagitis and symptomatic gastroesophageal reflux diseases.

The invention discloses a medicine composition for treating peptic ulcer, comprising the following components: 10-20 parts of radix codonopsis pilosulae, 5-15 parts of white atractylodes rhizome, 5-15parts of tuckahoe, 4-12 parts of tuber pinellia, 3-7 parts of rhubarb, 5-15 parts of angelica, 1-5 parts of costusroot, 5-15 parts of tangerine peel, 3-9 parts of villous anomum, 4-12 parts of corydalis tuber, 5-15 parts of salvia miltiorrhiza, 8-16 parts of white peony root, 3-7 parts of rhizoma atractylodis, 4-12 parts of radix bupleuri, 3-9 parts of baikal skullcap root, 3-7 parts of coptis root, 0.5-3 parts of fructus evodiae and 3-7 parts of licorice. The invention also provides a preparation method of the medicine composition, comprising the following steps: weighing each component, grinding, pulverizing, mixing, sieving with a sieve of 100 meshes and preparing various medicament forms which are acceptable in traditional Chinese medicine pharmaceutics. The medicine composition provided by the invention has the characteristics of good curative effect, no toxic or side effect and little possibility of relapse after recovery when being used for treating the peptic ulcer.

The invention provides an MG53 (mitsugumin53) mutant and a preparation method thereof. The mutant is a serine-site mutant of MG53 protein in a Coiled-coil structural domain, and the mutant results in inactivation of MG53 phosphorylation. Meanwhile, the MG53 protein mutant can be used for preventing or treating diseases related to cellular membrane damage, such as diseases related to myocardial cell injury, diseases related to ulcer, trauma with a wound, particularly a difficult-to-heal wound, intestinal leakage, kidney injury and the like. The diseases related to myocardial cell injury can include one or more diseases related to following symptoms: myocardial ischemia, heart ischemia, heart ischemia/reperfusion injury, myocardial infarction, cardiac failure, arrhythmia and cardiac rupture. The diseases related to ulcer include one or more of following diseases: chronic ulcer, peptic ulcer, diabetic foot ulcer, diabetic foot gangrene and chronic gastric ulcer. Besides, the invention further provides a dry powder preparation, a spray preparation, a gel preparation and an emulsion containing MG53 or MG53 mutant as well as preparation methods of the preparations.

The invention provides a composition. The composition is characterized by being prepared from the following ingredients in parts by weight: ginseng roots 1-15, poria cocos 3-25, Chinese yam 5-50, lotus seeds 2-25, coix seeds 3-50, white hyacinth beans 3-25, polished round-grained rice 20-400 or/and oats 20-400. The invention also relates to the application of the composition in health care food or medicines or products having functions of preventing and treating gastric mucosal damage caused by chronic gastritis, gastric ulcer or duodenal ulcer, relieving abdominal pain caused by the chronic gastritis or peptic ulcer and preventing and treating the syndrome of weakness of the spleen and the stomach.

The invention relates to an oral pharmaceutical composition preparation for treating peptic ulcer. The composition contains an acid-sensitive proton pump inhibitor, a gastric mucosa protective agent and a pharmaceutically acceptable carrier, wherein the proton pump inhibitor exists in a stable form. The invention also relates to a preparation method of the pharmaceutical composition. In the preparation method, two medicines are combined in a fixed unit preparation, thereby simplifying the medication scheme and improving the patient compliance.

The invention relates to a method for extracting and purifying Pinostrobin from medicinal plants, and a pharmaceutical preparation and application thereof. The invention particularly discloses a method for extracting and purifying Pinostrobin from medicinal plants, and a pharmaceutical preparation and application thereof in preparing medicines for treating gastroenteropathy, and belongs to the field of life sciences. The method comprises the following steps: extracting medicinal plants with 70-95% ethanol homogenate; and after the extract is concentrated to a certain volume, standing to precipitate, removing a supernatant, dissolving the obtained precipitate with an organic solvent, separating by gel-resin column chromatography, crystallizing and recrystallizing to obtain the Pinostrobin monomer of which the purity is higher than 90%. The Pinostrobin monomer in which different excipients can be added is prepared into any common pharmaceutical formulation. The pharmaceutical preparation has obvious biological activity on peptic ulcer, gastritis, stomachache, gastric evacuation (gasterectasis), alimentary tract tumors and the like caused by Helicobacter pylori infection, and has thecharacteristic of no toxic or side effect.

The invention belongs to the technical field of drugs, and relates to a compound tablet for treating peptic ulcer and a method for preparing the same. In the compound tablet, an anti acid agent (an H2 receptor blocking agent and a proton pump inhibitor) and an united synergic agent of an antibiotic or two types of antibiotics or disunited synergic agent are used as a tablet core. The tablet core comprises main materials and auxiliary materials, wherein the main materials consist of an anti acid agent, a stomach mucous membrane protective agent and one or two types of antibacterial agents; the dosage range of the anti acid agent is between 10 and 40mg, and the cyclodextrin is adopted for coating or self emulsification; the dosage range of each type of antibacterial drug is between 100 and 1,000mg; and the dosage range of the stomach mucous membrane protective agent is between 100 and 500mg. By adopting the reaction of the anti acid agent and the cyclodextrin to prepare a coating matter or for self emulsification, the anti acid agent is treated, and the treated anti acid agent, antibacterial drugs and proper amount of auxiliary materials are pressed into the tablet core, and the tablet core is externally coated with an enteric coating or pressed into the enteric coating. The compound tablet and the method have the advantages of obviously improving the stability and the bioavailability of the anti acid agent and the antibiotics, and simultaneously effectively lowering the irritation of certain antibiotics on stomach.

The invention discloses a preparation method of a medicine for treating peptic ulcers. The method comprises the following steps: (1) weighing raw medicinal materials in parts by weight: 17 to 23 parts of potentilla anserina, 7 to 12 parts of poria cocos, 5 to 9 parts of oriental wormwood, 5 to 9 parts of pogostemon cablin, 5 to 9 parts of raw malt, 3 to 7 parts of mangnolia officinalis, 3 to 7 parts of perilla leaves and 3 to 7 parts of caulis perllae; (2) pulverizing the potentilla anserina to form powder for later use; firstly adding 55-95v/v% (volume per volume) ethyl alcohol into the other medicinal materials except for the potentilla anserina for extracting, filtering to obtain an alcohol extract for later use, decocting filter residue by adding water, combining the alcohol extract with the filter residue, concentrating and then adding the potentilla anserina powder and pharmaceutically acceptable auxiliary materials so as to obtain the medicine. The medicine is less in medicinal flavor according to a specific dosage proportion, and can be used for effectively treating gastric ulcers, duodenal ulcers and erosive gastritis, thereby providing a new medicine selection for clinic treatment of the peptic ulcers. Meanwhile, the pharmacological test proves that the pharmacological activity of the medicine is improved in manners of double alcohol-water extraction and pulverization of the potentilla anserina into medicinal powder, so that the economical utilization of medicinal material resources is realized.

A Chinese medicine for treating gastric ulcer, duodenal ulcer and chronic gastritis is prepared from frankincense, peony root, aucklandia root and liquorice root.

The invention discloses a bacterial strain as well as a composition and application, and relates to the technical field of strain separation and application. The Cristinia sp. provided by the invention can be applied to treatment or prevention of liver function impairment and liver function impairment related diseases, alimentary canal mucosal injury and alimentary canal mucosal injury related diseases, diabetes, obesity and obesity related diseases. The inventor verifies that the Cristinia sp. provided by the invention has no toxic or side effect on the kidney and can reduce the weight of the liver; the initial steatohepatitis focus can be treated; fat accumulation of liver cells can be slowed down; AST and ALT in serum can be reduced; and abdominal white fat inflammatory lesion can be reduced. The Cristinia sp. can also repair the digestive tract mucosa, recover the barrier function of the mucosa, and prevent and treat intestinal leakage, peptic ulcer and other diseases caused by barrier function impairment. The Cristinia sp. also has the effects of reducing fasting blood-glucose of a body, regulating insulin level and reducing body fat of mammals, and has the effects of preventing and treating diabetes and improving the metabolic function of obese patients.